Nanobiotix Starts New NBTXR3 Study In Lung Cancer Patients
Nanobiotix (NASDAQ:NBTX) initiated a new Phase 1 study evaluating NBTXR3 activated by radiation therapy (RT) for patients with non-small cell lung…
NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer
NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the initiation of a new phase I
The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 3)
Nanobiotix’s Nanoparticle Technology Shows Tumor-Killing Effect in Early-Stage Head & Neck Cancer
Nanobiotix (NASDAQ:NBTX), ahead of the 2021 Annual Meeting of the American Society for Clinical Oncology meeting, has said that…
NANOBIOTIX Reports New Data For Potential First-In-Class Radioenhancer NBTXR3 In Combination With Anti-PD-1 Showing Local Or Distant Tumor Regression In 76.9% Of Evaluable Patients Regardless Of Prior Anti-PD-1 Exposure
Data to be Presented at the 2021 Annual Meeting of the American Society for Clinical Oncology
Results show NBTXR3 plus radiotherapy could potentially stimulate immune response and convert anti-PD-1 non-responders into
Nanobiotix, LianBio Ink NBTXR3 Development Pact In Asia For Solid Tumor Settings
Nanobiotix (NASDAQ: NBTX) has announced a partnership with LianBio to develop and commercialize Nanobiotix’s lead product candidate NBTXR3, in Greater China (mainland China, Hong…